Skip to main navigation
  • Company
    • About Us
    • Leadership
    • Collaboration
    • Contact
  • Pipeline
    • Pipeline
    • Clinical Trials
  • Patients
  • Technology
    • Multiclonics® Platform
    • Publications
  • Investors & Media
    • Investors & Media Home
    • Financial Information
      • SEC Filings
      • Extraordinary General Meeting December 2019
      • Annual General Meeting 2022
      • Annual General Meeting 2021
      • Extraordinary General Meeting December 2019
      • Annual General Meeting 2019
      • Annual General Meeting 2018
      • Annual General Meeting 2017
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
      • Governance Contacts
      • Governance Documents
    • News Releases
    • Event Calendar
    • Analyst Coverage
    • Stock Information
    • FAQ's
    • Email Alerts
  • Careers
Menu
 

Annual General Meeting 2021

Annual General Meeting 2021

Documents and Files
Merus – Voting results AGM 2021
May 28, 2021
Minutes 2021 AGM
May 28, 2021
Merus N.V. - NL - Deed of Amendment (B) AoA (forum selection clause)
May 7, 2021
Merus N.V. - ENG - Deed of Amendment (B) AoA (forum selection clause)
May 7, 2021
Dutch 2020 Board Report - Merus N.V.
May 7, 2021
Convening notice AGM 2021 Merus N.V
May 7, 2021
Merus N.V. - NL - Deed of Amendment (A) AoA (increase authorized capital)
May 7, 2021
Merus N.V. - ENG - Deed of Amendment (A) AoA (increase authorized capital)
May 7, 2021
Proxy Card AGM
April 29, 2021
Works Council Statement
April 29, 2021

Toolkit

  • RSS Feeds
  • E-mail Page
  • Print Page
  • E-mail Alerts
Explore
  • Company
  • Pipeline
  • Patients
  • Technology
  • Investors & Media
  • Careers
  • Contact
Contact Us

NL: +31 85 016 2500
Merus N.V., Uppsalalaan 17, 3rd & 4th floor, 3584 CT Utrecht, The Netherlands
US: +1 617 401 4499
139 Main Street, Cambridge, MA 02142, USA
enquiries@merus.nl

© 2023 Merus - All rights reserved. Privacy Statement, Online Tracking Opt-Out Guide, Terms of Use & Community Guidelines.